Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. develops marijuana and alcohol breath-testing technologies for workplace safety, law enforcement, and other safety-sensitive settings. Company news centers on the Marijuana Breath Test, or MBT, including its Breath Collection Unit and single-use Breath Cartridges used to collect breath samples for laboratory analysis of recent cannabis use.
Recurring updates include commercial rollout activity, deliveries through authorized resellers, product validation, regulatory and compliance testing for device hardware, and distribution or education efforts with testing-industry partners. News also covers the company’s work with Omega Laboratories on analytical methods for detecting cannabinoids in breath samples using LC-MS-based testing.
Cannabix Technologies (BLOZF) has received NHTSA approval for its BreathLogix Workplace Series alcohol breathalyzer. The device has met the USDOT model specifications for breath alcohol screening devices and will be added to the U.S. Federal Register Conforming Products List. The BreathLogix WS features rapid breath alcohol checking, simultaneous user photo capture, and real-time manager alerts.
Key features include precise BAC level detection, SMS/email test reports, integration capabilities with various access control systems, and patent-pending pre-calibrated sensor cartridge technology. The device is designed for multiple applications including construction, transportation, healthcare, manufacturing, and other safety-sensitive industries.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has signed a non-exclusive distribution agreement with Alco Prevention Canada for North America to distribute its BreathLogix autonomous alcohol breathalyzer devices. Alco Prevention, based in Montreal, has 4,000 points of sale and 45 agents worldwide.
The BreathLogix device features patent-pending pre-calibrated cartridge technology, eliminating the need for costly calibration equipment and technician visits. The system autonomously performs alcohol screening, captures user photos for identity confirmation, and delivers real-time BAC results with automated reporting via text, email, and web portal.
The device is currently being used by the Friedel Clinic in Montana under the 24/7 Sobriety Program, demonstrating cost and time savings by eliminating the need for dedicated screening administrators. The company is in discussions with additional distributors in North America and other regions.
Cannabix Technologies (OTC: BLOZF) announces its participation in the Tennessee Safety and Health Conference (TSHC) in Nashville starting April 7th, 2025. The company will showcase two key technologies alongside AlcoPro Inc.: the Marijuana Breath Test (MBT) and BreathLogix alcohol screening device.
The MBT is a portable breath collection system for detecting recent THC use, validated by Omega Laboratories in March 2025. It can detect multiple cannabinoids including Δ-9-THC, Δ-8-THC, CBD, and CBN. Unlike traditional testing methods, it focuses on a more relevant consumption window.
The BreathLogix series features unmanned wall-mounted alcohol screening devices with patent-pending pre-calibrated cartridge technology. These devices offer autonomous sobriety checking, identity confirmation, and real-time BAC level reporting via text, email, and web portal.
Additionally, the company announced a change in auditor from Saturna Group to SHIM and Associates LLP, effective April 4th, 2025.
Cannabix Technologies (OTC: BLOZF) announces its participation in the upcoming National Drug and Alcohol Screening Association (NDASA) conference in Florida, where it will showcase its Marijuana Breath Test (MBT) alongside strategic partner Omega Laboratories.
The announcement follows Omega Laboratories' recent validation of the Cannabix MBT, which can simultaneously quantify Δ-9-THC, Δ-8-THC, CBD, and CBN in breath aerosols. The MBT system, comprising a Breath Collection Unit and Breath Cartridge, focuses on detecting recent marijuana use, unlike traditional urine, blood, and saliva tests that can detect THC for extended periods.
With cannabis now legal for medical use in 39 states and recreational use in 24 states, Cannabix is positioning itself at the forefront of breath-based drug detection. The company is currently conducting an operational review to scale up manufacturing, sales, marketing, and support capabilities in anticipation of growing demand.
Omega Laboratories has successfully completed method validation for a marijuana breath test using Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) Breath Collection Unit (BCU). The validated test method can simultaneously quantify THC, Δ-8-THC, CBD, and CBN in breath aerosols.
The Cannabix BCU features advanced capabilities including start-up air flow self-check, ambient air sample collection, split sample A/B configuration, and anti-cheating mechanisms. The system utilizes mass spectrometry for analysis, ensuring high forensic standards.
This breakthrough enables detection of recent marijuana use (within minutes to several hours), addressing limitations of traditional testing methods that detect usage over extended periods. Omega Laboratories is now incorporating breath testing into its service offerings, positioning the partnership as a leading solution for employers facing challenges with cannabis detection in various industries including law enforcement, workplace safety, and healthcare.
Cannabix Technologies (CSE: BLO) (OTC PINK: BLOZF) has signed a memorandum of understanding (MOU) with AlcoPro Inc. of Knoxville, TN, to collaborate on marketing the Cannabix Marijuana Breathalyzer (CMB) technology in the United States. As part of the initial agreement, AlcoPro will feature the CMB hardware in its 2025 product catalogue, which reaches over 70,000 businesses globally.
AlcoPro, established in 1982, is a leading distributor of drug and alcohol testing instruments. The MOU aims to establish preliminary marketing exposure for the CMB to AlcoPro's customers, assess market interest, and work towards a future distribution agreement. Cannabix has recently upgraded its Breath Collection Unit (BCU), a key hardware component used for portable detection of delta-9 THC in breath, and is advancing its validation work in the United States.
Cannabix Technologies (CSE: BLO, OTC: BLOZF) has announced significant updates to its Cannabix Marijuana Breathalyzer (CMB) technology. The company has enhanced its Breath Collection Unit (BCU) with new features including a smaller, lightweight design, removable rechargeable Li-ion battery, and modified sample collection cartridge capable of single or dual sample collection.
The improvements come amid growing concerns about marijuana-impaired driving in the United States, where cannabis is now legal in 39 states for medical use and 24 states for recreational use. According to a 2019 AAA Foundation survey, approximately 14.8 million U.S. drivers reported driving within one hour of using marijuana, with 70% believing they wouldn't get caught.
The technology focuses on 'recent use' detection of delta-9 THC, unlike traditional urine, blood, and saliva tests that can detect THC weeks after consumption. New features include ambient air collection capability, periodic quality assurance checks, and a streamlined user interface.
Cannabix Technologies has received positive certification from CEcert GmbH for its Breath Logix autonomous alcohol breathalyzer. The certification follows rigorous 6-month testing under Australian Standard AS 3547.1, including alcohol, drift, climatic, electromagnetic compatibility, and vibration testing. This certification enables marketing and sales in Australia and other jurisdictions. The device features patent-pending pre-calibrated cartridge technology, autonomous sobriety checking, identity confirmation, and real-time BAC reporting. The company is partnering with Breathalyser Sales & Service Pty for distribution in Australia, targeting employers, alcohol testing facilities, and various safety-critical industries including mining, oil and gas, industrial, trucking, and warehousing.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) announced its participation in the upcoming Society of Forensic Toxicologists (SOFT) conference in October. Dr. Bruce Goldberger, Senior Advisor to Cannabix, will present the company's marijuana breathalyzer system at a workshop session titled 'Chasing Impairment – Advancement in Technologies or a Paradigm Shift? – You be the Judge!'
In collaboration with Omega Laboratories Inc., Cannabix has upgraded its Breath Collection Unit with new features to meet market and regulatory requirements. These include an 'on demand' quality assurance check, a startup self-check, and a new ambient air sample collection procedure. The sample collection cartridge has been modified to collect single or dual samples.
Omega scientists have successfully detected and quantified delta-9 THC in the low picogram range using Cannabix's technology. They have also developed a test method that detects, isolates, and quantifies delta-9 THC, delta-8 THC, CBN, and CBD from breath samples. The partnership aims to advance the development and commercialization of Cannabix's marijuana breathalyzer technology.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has initiated advanced discussions with Smartox of Irving, Texas for potential sales distribution of its Breath Logix Alcohol screening device. The company has shipped the device for evaluation, preliminary marketing, and business development purposes. Cannabix is rapidly advancing its Breath Logix alcohol screening devices with certification, manufacturing, regulatory, and distribution relationships.
The Breath Logix device offers a fast, accurate, and autonomous alcohol screening process for workplace testing. It features a unique pre-calibrated, replaceable alcohol sensor cartridge, eliminating costly calibrations. The device integrates with third-party access control and biometric systems, potentially expanding the reach of alcohol device distributors worldwide.